Zylox-Tonbridge Medical Technology Co (FRA:818) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:818 Zylox-Tonbridge Medical Technology Co Ltd FRA:818
76 GF Score
Price €2.08
GF Value €3.72
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Zylox-Tonbridge Medical Technology Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Zylox-Tonbridge Medical Technology Co Valuation Rank Related Terms

FRA:818
76GF Score
Zylox-Tonbridge Medical Technology Co Ltd FRA:818
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zylox-Tonbridge Medical Technology Co (FRA:818) Overvalued in 2026?

Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued. The current stock price of €2.08 is trading 44.1% below its estimated GF Value™ of €3.72. GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.

Key valuation signals for FRA:818:

  • Valuation Rank:
  • GF Value™: €3.72 vs. price of €2.08 (44.1% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the FRA:818 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zylox-Tonbridge Medical Technology Co Business Description

Other Exchanges 02190:Hong Kong
Address 270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
76GF Score

Get the complete analysis for FRA:818

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.08
Price
€3.72
GF Value